Jon Ruckle

866 total citations
22 papers, 672 citations indexed

About

Jon Ruckle is a scholar working on Molecular Biology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jon Ruckle has authored 22 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pharmacology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jon Ruckle's work include Pharmacogenetics and Drug Metabolism (3 papers), Pharmaceutical studies and practices (3 papers) and HIV Research and Treatment (2 papers). Jon Ruckle is often cited by papers focused on Pharmacogenetics and Drug Metabolism (3 papers), Pharmaceutical studies and practices (3 papers) and HIV Research and Treatment (2 papers). Jon Ruckle collaborates with scholars based in United States, Switzerland and Canada. Jon Ruckle's co-authors include Mark Jacobs, William G. Kramer, Matthew L. Sherman, Yijun Yang, Carolyn H. Condon, Amelia E. Pearsall, Kathryn Underwood, Ravindra Kumar, Jasbir Seehra and Le T. Vuong and has published in prestigious journals such as Gastroenterology, American Journal of Clinical Nutrition and Neurology.

In The Last Decade

Jon Ruckle

21 papers receiving 641 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jon Ruckle United States	12	248	118	94	90	76	22	672
Jenny Chau China	12	328 1.3×	113 1.0×	117 1.2×	50 0.6×	38 0.5×	17	961
Theo Nell South Africa	17	223 0.9×	64 0.5×	131 1.4×	46 0.5×	43 0.6×	32	783
Antonio Vella Italy	17	176 0.7×	135 1.1×	103 1.1×	39 0.4×	72 0.9×	48	851
Sarah Shugarts United States	9	130 0.5×	259 2.2×	47 0.5×	25 0.3×	40 0.5×	13	691
Howard Sussman United States	10	234 0.9×	88 0.7×	50 0.5×	22 0.2×	20 0.3×	10	679
B. M. Frey Switzerland	22	238 1.0×	94 0.8×	77 0.8×	32 0.4×	85 1.1×	44	1.0k
Chunmei Li China	22	525 2.1×	100 0.8×	243 2.6×	15 0.2×	31 0.4×	66	1.1k
Marcel J.W. Janssen Netherlands	12	203 0.8×	65 0.6×	47 0.5×	10 0.1×	92 1.2×	25	621
Fuu‐Jen Tsai Taiwan	16	295 1.2×	83 0.7×	68 0.7×	28 0.3×	92 1.2×	52	693
H.M.J. Roelofs Netherlands	12	345 1.4×	113 1.0×	146 1.6×	34 0.4×	62 0.8×	22	789

Countries citing papers authored by Jon Ruckle

Since Specialization

Citations

This map shows the geographic impact of Jon Ruckle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Ruckle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Ruckle more than expected).

Fields of papers citing papers by Jon Ruckle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Ruckle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Ruckle. The network helps show where Jon Ruckle may publish in the future.

Co-authorship network of co-authors of Jon Ruckle

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Ruckle. A scholar is included among the top collaborators of Jon Ruckle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Ruckle. Jon Ruckle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barbour, Sean, Michelle Hladunewich, Angela Makris, et al.. (2024). Phase II Results of an Investigational RNA Therapeutic to Complement Factor B, IONIS-FB-LRx, for Treatment of IgA Nephropathy. Journal of the American Society of Nephrology. 35(10S).

Barbour, Sean, Michelle Hladunewich, Angela Makris, et al.. (2022). An Exploratory Trial of an Investigational RNA Therapeutic, IONIS-FB-LRx, for Treatment of IgA Nephropathy. Journal of the American Society of Nephrology. 33(11S). 800–800. 4 indexed citations

Parasrampuria, Dolly A., et al.. (2022). Single Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects (P14-8.001). Neurology. 98(18_supplement). 2 indexed citations

Parasrampuria, Dolly A., et al.. (2022). A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects (P14-8.002). Neurology. 98(18_supplement). 1 indexed citations

Ruckle, Jon, Stewart A. Turner, Kathe Stauber, et al.. (2019). P139 OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) – PRECLINICAL AND EARLY CLINICAL DEVELOPMENT. Inflammatory Bowel Diseases. 25(Supplement_1). S64–S64. 1 indexed citations

Walicke, Patricia A., Franz Hefti, Shiao-Ping Lu, et al.. (2018). First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain. PAIN Reports. 3(3). e653–e653. 11 indexed citations

Glorieux, Francis H., Jean‐Pierre Devogelaer, Michaela Durigova, et al.. (2017). BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. Journal of Bone and Mineral Research. 32(7). 1496–1504. 107 indexed citations

Krishna, Rajesh, Ferdous Gheyas, Yang Liu, et al.. (2017). Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects. The Journal of Clinical Pharmacology. 58(2). 254–262. 4 indexed citations

Burt, Tal, Christy S. John, Jon Ruckle, & Le T. Vuong. (2016). Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans – a practical guide. Expert Opinion on Drug Delivery. 14(5). 657–672. 27 indexed citations

10.

Chinsangaram, Jarasvech, Kady M. Honeychurch, Shanthakumar Tyavanagimatt, et al.. (2012). Safety and Pharmacokinetics of the Anti-Orthopoxvirus Compound ST-246 following a Single Daily Oral Dose for 14 Days in Human Volunteers. Antimicrobial Agents and Chemotherapy. 56(9). 4900–4905. 46 indexed citations

11.

Ross, Alastair B., Le T. Vuong, Jon Ruckle, et al.. (2011). Lycopene bioavailability and metabolism in humans: an accelerator mass spectrometry study. American Journal of Clinical Nutrition. 93(6). 1263–1273. 59 indexed citations

12.

Herman, Gary, Goutam C. Mistry, Bingming Yi, et al.. (2010). Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British Journal of Clinical Pharmacology. 71(3). 429–436. 29 indexed citations

13.

Wasnich, Richard D., et al.. (2010). Contribution of a Heating Element to Topical Anesthesia Patch Efficacy Prior to Vascular Access: Results From Two Randomized, Double-Blind Studies. Journal of Pain and Symptom Management. 40(4). 510–519. 17 indexed citations

14.

Schwartz, Jules I., Mark Stroh, Bing Gao, et al.. (2009). Effects of Laropiprant, a Selective Prostaglandin D₂ Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone. Cardiovascular Therapeutics. 27(4). 239–245. 4 indexed citations

15.

Scott, Daniel A., et al.. (2008). Phase 1 trial of 13‐valent pneumococcal conjugate vaccine in Japanese adults. Pediatrics International. 50(3). 295–299. 31 indexed citations

16.

Ruckle, Jon, Mark Jacobs, William G. Kramer, et al.. (2008). Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women. Journal of Bone and Mineral Research. 24(4). 744–752. 171 indexed citations

17.

Vuong, Le T., Jon Ruckle, Arlin B. Blood, et al.. (2007). Use of Accelerator Mass Spectrometry to Measure the Pharmacokinetics and Peripheral Blood Mononuclear Cell Concentrations of Zidovudine. Journal of Pharmaceutical Sciences. 97(7). 2833–2843. 31 indexed citations

18.

Greig, Nigel H., et al.. (2005). Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects. Current Alzheimer Research. 2(4). 483–492. 31 indexed citations

19.

Labellarte, Michael J., Joseph Biederman, Graham J. Emslie, et al.. (2004). Multiple-Dose Pharmacokinetics of Fluvoxamine in Children and Adolescents. Journal of the American Academy of Child & Adolescent Psychiatry. 43(12). 1497–1505. 15 indexed citations

20.

Ruckle, Jon, et al.. (2001). Safety and Pharmacokinetics of Single Doses of (+)-Calanolide A, a Novel, Naturally Occurring Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy, Human Immunodeficiency Virus-Negative Human Subjects. Antimicrobial Agents and Chemotherapy. 45(5). 1379–1386. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact